Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Bioniche Phase III Clinical Trial With Urocidin(TM) Progressing Well
Bioniche Life Sciences Inc. ("Bioniche"; TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guerin (BCG).
generic viagra online
In Mouse Study Immune Cells Ameliorate Hypertension-Induced Cardiac Damage
Researchers in Berlin, Germany have found that a specific type of immune cell, the regulatory T lymphocyte (Treg) plays an important role in hypertension-induced cardiac damage. The injected Treg that they harvested from donor mice into recipient mice were infused with angiotensin II, a blood pressure-raising peptide. The Tregs had no influence on the blood pressure response to angiotensin II. Nonetheless, cardiac enlargement, fibrosis, and inflammation was sharply reduced by Treg treatment. Furthermore, the tendency to develop abnormal heart rhythms that could lead to sudden cardiac death was also reduced. Dr. Heda Kvakan and Dr. Dominik N. MÃøller at the Experimental and Clinical Research Center at the Max DelbrÃøck Center do not intend Treg as a therapy. However, a better understanding of how the immune system fits into hypertension-induced organ damage could result from these studies (Circulation, Vol. 119, No. 22, June 9, 2009, 2904-2912 ).*
News of the day
Scientists Track Chemical Changes In Cells As They Endure Extreme Conditions
One of nature"s most gripping feats of survival is now better understood. For the first time, scientists from the U.S. Department of Energy"s Lawrence Berkeley National Laboratory observed the chemical changes in individual cells that enable them to survive conditions that should kill them.
Nutrition

Researchers Say More Aggressive Vitamin D Supplementation Needed In Obese Cancer Patients

Body mass index (BMI) should be taken into account when assessing a cancer patient"s vitamin D status, according to researchers at Cancer Treatment Centers of America (CTCA), who found that obese cancer patients had significantly lower levels of vitamin D compared to non-obese patients. The association between vitamin D and obesity remains unsettled with studies reporting conflicting findings on the relationship between the two. This association assumes even greater importance in cancer because of the alleged role of vitamin D in cancer. "Currently, the dietary recommendations for vitamin D do not take into account a patient"s BMI," said Carolyn Lammersfeld, national director of nutrition for CTCA and a principal investigator in the study. "We investigated the relationship between vitamin D and BMI in a large sample of cancer patients and found that as BMI groups increased from normal to overweight or obese classifications, there was a significant decrease in vitamin D." The researchers evaluated a group of 740 cancer patients seen at CTCA from January 2008 to June 2008. Of the 740 patients, 303 were male and 437 female, with a mean age at presentation of 55.7 years (SD = 10.2). The mean BMI was 27.9 kg/m2 (SD = 6.7). The most common cancers were lung (134, 18.1%), breast (131, 17.7%), colorectal (97, 13.1%), pancreatic (86, 11.6%), prostate (45, 6.1%) and ovarian (39, 5.3%). The mean vitamin D (serum 25(OH)D) was 21.9 ng/ml (SD = 13.5). The study concluded that obese cancer patients (BMI >=30 kg/m2) had significantly lower levels of vitamin D compared to non-obese patients (BMI About Cancer Treatment Centers of America Founded in 1988, Cancer Treatment Centers of America (CTCA) is a national network of hospitals providing a comprehensive, fully integrative approach to cancer treatment. CTCA serves patients with advanced cancer from all 50 states at facilities located in suburban Chicago, Philadelphia, Tulsa and suburban Phoenix. Cancer Treatment Centers of America


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009